At NeOncoFRAx, we believe that every tumor carries a unique genetic fingerprint—one that can be decoded to help the immune system distinguish friend from foe. By analyzing the DNA of a patient’s tumor, we identify specific mutations that generate neoantigens: protein fragments that exist only in cancer cells. Our vaccines utilize these tumor-specific markers to train the immune system to recognize and eliminate malignant cells, while sparing healthy tissue.
Our vaccines present these neoantigens to the immune system, priming T cells to recognize and destroy the cancer. This precision approach offers the potential for greater efficacy and lower toxicity compared to conventional immunotherapies.
We are launching our program in resected pancreatic ductal adenocarcinoma (PDAC)—one of the most aggressive and treatment-resistant cancers. Despite surgery, relapse rates are high, and survival remains poor. Its immunological resistance and low responsiveness to current therapies make PDAC an ideal testing ground for new immunotherapeutic strategies.
Our initial trials aim to demonstrate feasibility, safety, and sustained immune activation in this challenging setting. However, our ambitions extend further: the long-term goal is to expand our platform to other solid tumors with high unmet medical needs and limited immune responsiveness.
We believe pancreatic cancer is not a one-size-fits-all disease. Each tumor carries a unique set of mutations. By tailoring the vaccine to the individual’s tumor, we can:
Personalization increases the likelihood of meaningful responses in cancers traditionally considered non-immunogenic.
Neoantigens are protein fragments produced by tumor-specific mutations. Because these mutations do not occur in healthy cells, they provide ideal targets for immune attack with minimal risk of harming normal tissue.
NeOncoFRAx has a strong focus on providing its therapeutic solution at a societally fair price. Fully owned by the Erasmus MC Holding, the company has a strong connection with the academic organization, ensuring that it has access to the full range of Erasmus MC’s developmental capabilities. We run the majority of our development pipeline through this collaboration, minimizing reliance on other contractors. This integrated approach reduces both time and cost while ensuring consistent quality, regulatory compliance, and scientific oversight.
